A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Description

N/A

Nodular lymphocyte predominant Hodgkin lymphoma
Cerebral/meningeal disease, including signs and symptoms of progressive multifocal leukoencephalopathy (PML)
Pulmonary diffusion capacity > 25% lower than normal predicted value
Sensory or motor peripheral neuropathy
Known human immunodeficiency virus (HIV) positive
Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection Please note that there are additional exclusion criteria. The study center will determine if you meet all of the criteria.

Please contact Anayansi Miloud to learn more about where you can participate in this trial. Please use the contact form on the right side.